Saturday, March 7, 2020
Boston Marriott Copley Place
BOSTON
Charles Flexner, Johns Hopkins University
Where are we LEAPing Next?! and Overview of Workshop
[audio-only/slide]
PLENARY SESSION 1: Current Status of Existing Technologies:
10-Minute Presentations followed by Q & A (Charles Flexner, Moderator):
Peter Williams, Janssen
Current status of the Janssen LA/ER pipeline
[audio-only/slide]
William Spreen, ViiV Healthcare
Current status of the ViiV LA/ER pipeliner
[audio-only/slide]
Jay Grobler, Merck
Current status of the Merck LA/ER pipeline
[audio-only/slide]
Martin Rhee, Gilead Sciences
Current status of the Gilead LA/ER pipeline
[audio-only/slide]
Janssen, ViiV, Merck, Gilead
Industry Panel Discussion, Q&A
[audio-only/slide]
Mark Mirochnick, Boston University
Status of Infant and Pediatric Development Programs for LA ARV Formulations
[audio-only/slide]
Marco Siccardi, University of Liverpool
Update from the LEAP Modeling and Simulation Core
[audio-only/slide]
Plenary Session 2: Novel approaches to LA/ER Drug Delivery:
10-Minute Presentations followed by Five-Minute Q & A (Andrew Owen, Moderator)
Leah Johnson, RTI
Bioerodable Tenofovir Implants for HIV Prevention
[audio-only/slide]
Eric Appel, Stanford University
Injectable Hydrogels for the Ultra-Long Term Stabilization and Delivery of Anti-HIV Drugs
[audio-only/slide]
S. Rahima Benhabbour, UNC Chapel Hill
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
[audio-only/slide]
Ryan Donnelly, Queens University
Transcutaneous Microneedles for Antiretroviral Drug Delivery
[audio-only/slide]
Cherise Scott, Unitaid
Unitaid Programs to Support the Development of LA formulations for HIV, Tuberculosis, and Malaria
[audio-only/slide]
Participant Discussion
The Future Role of LEAP in Long-acting Drug and Formulation Development
[audio-only]